(Q37321948)

19 August 2017

1 reference

title

Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults (English)

1 reference

growth hormone deficiency

19 August 2017

main subject

1 reference

8

A Colao

1 reference

19 August 2017

6

E Ghigo

1 reference

19 August 2017

1

A Giustina

1 reference

19 August 2017

A Barkan

2

1 reference

19 August 2017

P Chanson

3

1 reference

19 August 2017

A Grossman

4

1 reference

19 August 2017

A Hoffman

5

1 reference

19 August 2017

F Casanueva

7

1 reference

19 August 2017

S Lamberts

9

1 reference

19 August 2017

M Sheppard

10

1 reference

19 August 2017

S Melmed

11

1 reference

19 August 2017

Pituitary Society

12

1 reference

19 August 2017

European Neuroendocrine Association

13

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Journal of Endocrinological Investigation

19 August 2017

published in

1 reference

19 August 2017

volume

31

1 reference

19 August 2017

issue

9

1 reference

19 August 2017

page(s)

820-838

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03349263

19 August 2017

exact match

0 references

cites work

Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Systemic complications of acromegaly: epidemiology, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Epidemiology of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Pitfalls in the biochemical assessment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Normal growth and development in the absence of hepatic insulin-like growth factor I

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Clinically silent somatotropinomas may be biochemically active

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

A nationwide survey of mortality in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Pituitary surgery for the management of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Laryngoscopy and fibreoptic intubation in acromegalic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Anaesthetic complications of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Novel chimeric somatostatin analogs: facts and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Evolving concepts in the quest for advanced therapeutic analogues of somatostatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Guidelines for acromegaly management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Epidemiology of acromegaly in the Newcastle region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Sandostatin LAR in acromegalic patients: long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Primary medical therapy for acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Growth hormone receptor antagonist improves insulin resistance in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Somatostatin analogs in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of Acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Consensus statement: medical management of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Drugs and valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Growth hormone outgrows growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Which adults develop side-effects of growth hormone replacement?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Life expectancy following surgery for pituitary tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Increased cerebrovascular mortality in patients with hypopituitarism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Premature mortality due to cardiovascular disease in hypopituitarism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Insulin-like growth factors and neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

The oncogenic potential of autocrine human growth hormone in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Experience in management of 51 non-functioning pituitary adenomas: indications for post-operative radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Current guidelines for adult GH replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. .

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Fracture rates in patients with growth hormone deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Treatment of the adult growth hormone deficiency syndrome: directions for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Growth hormone therapy and quality of life in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Differential effect sizes of growth hormone replacement on Quality of Life, well-being and health status in growth hormone deficient patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349263

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

21 January 2018

1 reference

12 December 2020

The pathology of median neuropathy in acromegaly

1 reference

12 December 2020

Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?

1 reference

12 December 2020

Determinants of clinical outcome and survival in acromegaly

1 reference

12 December 2020

Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission

1 reference

12 December 2020

Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency.

1 reference

12 December 2020

Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly

1 reference

12 December 2020

Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years

1 reference

12 December 2020

Current diagnostic guidelines for biochemical diagnosis of acromegaly.

1 reference

12 December 2020

Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

1 reference

12 December 2020

Preoperative short-term administration of octreotide for facilitating transsphenoidal removal of invasive growth hormone-secreting macroadenomas

1 reference

12 December 2020

Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults

1 reference

12 December 2020

Current treatment guidelines for acromegaly

1 reference

12 December 2020

Long-term outcome of patients with acromegaly and congestive heart failure

1 reference

12 December 2020

Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly

1 reference

12 December 2020

Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt

1 reference

12 December 2020

Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas

1 reference

12 December 2020

Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly

1 reference

12 December 2020

Human growth hormone and human aging

1 reference

12 December 2020

Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation

1 reference

12 December 2020

Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients

1 reference

12 December 2020

Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients.

1 reference

12 December 2020

Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly

1 reference

12 December 2020

Growth hormone treatment in hypopituitary GH deficient adults reduces circulating cortisol levels during hydrocortisone replacement therapy

1 reference

12 December 2020

Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly

1 reference

12 December 2020

Effect of octreotide pretreatment on surgical outcome in acromegaly

1 reference

12 December 2020

Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.

1 reference

12 December 2020

Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations

1 reference

12 December 2020

GH deficiency in the adult and bone.

1 reference

12 December 2020

Acromegaly--the place of the neurosurgeon

1 reference

12 December 2020

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient

1 reference

12 December 2020

Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.

1 reference

12 December 2020

Presurgical Octreotide: treatment in acromegaly

1 reference

12 December 2020

Effect of the acid-labile subunit on the binding of insulin-like growth factor (IGF)-binding protein-3 to [125I]IGF-I

1 reference

12 December 2020

Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results

1 reference

12 December 2020

Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment

1 reference

12 December 2020

Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women

1 reference

12 December 2020

Factors influencing mortality in acromegaly

1 reference

12 December 2020

Diagnosis and treatment of acromegaly complications.

1 reference

12 December 2020

BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide

1 reference

12 December 2020

Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study

1 reference

12 December 2020

Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening

1 reference

12 December 2020

Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly

1 reference

12 December 2020

Comment on growth hormone therapy and retinal changes mimicking diabetic retinopathy

1 reference

12 December 2020

Criteria for cure of acromegaly: a consensus statement

1 reference

12 December 2020

Acromegaly and cancer: not a problem?

1 reference

12 December 2020

Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls

1 reference

12 December 2020

Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy

1 reference

12 December 2020

Resistance to somatostatin analogs in acromegaly: an evolving concept?

1 reference

12 December 2020

The effect of hypopituitarism on life expectancy

1 reference

12 December 2020

Clinical manifestations of acromegaly.

1 reference

12 December 2020

Mortality in acromegaly

1 reference

12 December 2020

Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory?

1 reference

12 December 2020

A comparison of lanreotide and octreotide LAR for treatment of acromegaly

1 reference

12 December 2020

Clinical perspective: acromegaly and cancer: a problem

1 reference

12 December 2020

Octreotide as primary therapy for acromegaly.

1 reference

12 December 2020

Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency

1 reference

12 December 2020

1 reference

12 December 2020

Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years

1 reference

12 December 2020

Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly

1 reference

12 December 2020

Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency?

1 reference

12 December 2020

Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly

1 reference

12 December 2020

Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

1 reference

12 December 2020

Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms.

1 reference

12 December 2020

Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients

1 reference

12 December 2020

An audit of outcome of treatment in acromegaly.

1 reference

12 December 2020

American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children--2003 update

1 reference

12 December 2020

New approach to the diagnosis of growth hormone deficiency in adults

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03349263

1 reference

19 August 2017

1 reference